BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Information Letter on acitretin and teratogenicity: Extension of the contraception period and the prohibition of blood donation after end of therapy

Active substance: acitretin

In an Information Letter, the companies Dermapharm and Puren Pharma point out the extension of the contraception period and the prohibition of blood donation up to three years after discontinuation of therapy with acitretin.

Download DHPC/Information letter , Download_VeroeffentlichtAm_EN PDF, 98KB, File is accessible